Akorn, Inc. Signs A Definitive Exclusive Development And Supply Agreement With Sofgen To Develop And Commercialize An ANDA Drug Product
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Aug. 10, 2006--Akorn, Inc. (AMEX:AKN) today announced that it has signed a definitive exclusive development and supply agreement to develop and commercialize an ANDA drug product. Sofgen Pharmaceuticals is a privately held pharmaceutical company located in Sunrise, Florida.